Literature DB >> 14688834

Pancreatic cancer - a continuing challenge in oncology.

Attila Zalatnai1.   

Abstract

Pancreatic cancer is still one of the major health problems because of its rising incidence and the modest therapeutic results. The paper surveys the statistical data, the risk factors, the preneoplastic ductal lesions, the hormonal sensitivity, the possible transdifferentiation in the endocrine and exocrine parts and the possibilities for chemoprevention. Hungary is peculiar among the European countries because during the last 50 years the incidence of pancreatic cancer has displayed a 15-fold increase. Apart from smoking, additional risk factors seem to be important, and recently a puzzling association between Helicobacter pylori seropositivity and pancreatic cancer was found. First-degree relatives of patients with pancreatic cancer are also at increased risk of this tumor. The term pancreatic intraepithelial neoplasia (PanIN) seems yet to be established, but the dynamics of these lesions needs to be further elucidated. Several lines of firmly established data indicate the hormonal sensitivity of this tumor, but still an unexplained discrepancy exists between the experimental and the clinical results. In addition to the somatostatin analogs, anti-gastrin vaccine is being tested. The mixed exocrine-endocrine tumors might suggest a real possibility of transdifferentiation between different compartments of the pancreas. Finally, the paper outlines the available data about the possibility of chemoprevention, including the role of cyclooxygenase inhibitors.

Entities:  

Mesh:

Year:  2003        PMID: 14688834     DOI: 10.1007/BF02893388

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  152 in total

1.  Evidence of chromosome instability in chronic pancreatitis.

Authors:  A S Cottliar; A F Fundia; C Morán; E Sosa; P Geldern; J C Gómez; N Chopita; I R Slavutsky
Journal:  J Exp Clin Cancer Res       Date:  2000-12

Review 2.  Survival statistics gone awry: pancreatic cancer, a case in point.

Authors:  Birgir Gudjonsson
Journal:  J Clin Gastroenterol       Date:  2002-08       Impact factor: 3.062

3.  Trends in cancer mortality in Switzerland, 1951-1984.

Authors:  F Levi; A Decarli; C La Vecchia
Journal:  Rev Epidemiol Sante Publique       Date:  1988       Impact factor: 1.019

4.  Expression of somatostatin receptor subtype 1-5 genes in human pancreatic cancer.

Authors:  W E Fisher; T A Doran; P Muscarella; L G Boros; E C Ellison; W J Schirmer
Journal:  J Natl Cancer Inst       Date:  1998-02-18       Impact factor: 13.506

5.  Neuroendocrine markers in adenocarcinomas: an investigation of 356 cases.

Authors:  Gen-You Yao; Ji-Lin Zhou; Mao-De Lai; Xiao-Qing Chen; Pei-Hui Chen
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

Review 6.  Familial pancreatic cancer.

Authors:  A P Klein; R H Hruban; K A Brune; G M Petersen; M Goggins
Journal:  Cancer J       Date:  2001 Jul-Aug       Impact factor: 3.360

7.  Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer.

Authors:  B T Brett; S C Smith; C V Bouvier; D Michaeli; D Hochhauser; B R Davidson; T R Kurzawinski; A F Watkinson; N Van Someren; R E Pounder; M E Caplin
Journal:  J Clin Oncol       Date:  2002-10-15       Impact factor: 44.544

8.  Pancreatic cancer mortality and organochlorine pesticide exposure in California, 1989-1996.

Authors:  Tim Clary; Beate Ritz
Journal:  Am J Ind Med       Date:  2003-03       Impact factor: 2.214

9.  Relevance of Somatostatin Receptors and Other Peptide Receptors in Pathology.

Authors:  Jean Claude Reubi
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

10.  Direct correlation between proliferative activity and dysplasia in pancreatic intraepithelial neoplasia (PanIN): additional evidence for a recently proposed model of progression.

Authors:  Walter M Klein; Ralph H Hruban; Andres J P Klein-Szanto; Robb E Wilentz
Journal:  Mod Pathol       Date:  2002-04       Impact factor: 7.842

View more
  6 in total

1.  Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer.

Authors:  Jing-Ting Jiang; Chang-Ping Wu; Hai-Feng Deng; Ming-Yang Lu; Jun Wu; Hong-Yu Zhang; Wen-Hui Sun; Mei Ji
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

2.  Early diagnosis of pancreatobiliary duct malignancies by brush cytology and biopsy.

Authors:  Gábor Elek; Tibor Gyökeres; Eszter Schäfer; Mária Burai; Ferenc Pintér; Akos Pap
Journal:  Pathol Oncol Res       Date:  2005-09-29       Impact factor: 3.201

3.  High gene expression of semaphorin 5A in pancreatic cancer is associated with tumor growth, invasion and metastasis.

Authors:  Anguraj Sadanandam; Michelle L Varney; Seema Singh; Abdelkader E Ashour; Nicolas Moniaux; Shonali Deb; Subodh M Lele; Surinder K Batra; Rakesh K Singh
Journal:  Int J Cancer       Date:  2010-09-01       Impact factor: 7.396

4.  The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer.

Authors:  Jennifer M Curry; Kyle J Thompson; Shanti G Rao; Dahlia M Besmer; Andrea M Murphy; Valery Z Grdzelishvili; William A Ahrens; Iain H McKillop; David Sindram; David A Iannitti; John B Martinie; Pinku Mukherjee
Journal:  J Surg Oncol       Date:  2013-01-17       Impact factor: 3.454

5.  H pylori infection causes chronic pancreatitis in Mongolian gerbils.

Authors:  Gabriele Rieder; Arno Karnholz; Mechthild Stoeckelhuber; Juanita L Merchant; Rainer Haas
Journal:  World J Gastroenterol       Date:  2007-08-07       Impact factor: 5.742

6.  Celecoxib combined with salirasib strongly inhibits pancreatic cancer cells in 2D and 3D cultures.

Authors:  Dongli Li; Yuran Ma; Wenfeng Liu; Xiang Ren; Min Chen; Xuetao Xu; Zhaojun Sheng; Kun Zhang; Renping Zhou; Susan Goodin; Xi Zheng
Journal:  Int J Med Sci       Date:  2020-07-09       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.